AbbVie’s Skin Disease Drug Hits Phase 3 Goal, but Efficacy Falls Short of Benchmarks: Analyst

기사 요약

AbbVie reports Phase 3 INTREPID trial results for lutikizumab in treating moderate to severe cases of hidradenitis suppurativa.